Results 191 to 200 of about 1,403,082 (309)

Session I: Molecular Oncology, Cytokines, New Treatment Modalities, Clinical Pharmacology [PDF]

, 2001
Vmcenzo Damano, Fartnnato Cnrdieoo, Ron Caputo, Gabneua Fontanrni, Divide Mehsi, Dc Sabmo, Raffaefc Anjelo, Franco Banco, Giampaolo Zunmo, Canedra Tortora, Oocologia b, Umversrta Mwhca, Fa Degh Stadi, Damek Santmi, Bruno Vmcemi, Alfredo Salerno, Rolando Angeuflo, Fabnzio Bartaknri, Donana Laodi, V. Leoni, Costantmo Cnnpm, Giordano Coonzo, Giuseppe Toomi, Umvemuv Campos Bio-Medxo, Luigi Ceuo, E. Bajetta, Leonardo Ferrari, Roberto Buzzonj, Raffaefte Longanm, Monica Lo Veccbio, Alfonso Marchjano, Robeno Labianca, Costanza Dardi, Alfonso Gentile   +33 more
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Towards greener and more sustainable pre-clinical oncology research. [PDF]

BJC Rep
Campion C, Robertson L, Stansfield I, Speirs V.   +3 more
europepmc   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Clinical Oncology Society of Australia Annual Scientific Meeting, November 13-15, 2024. [PDF]

Lancet Reg Health West Pac
Caga-Meller J.
europepmc   +1 more source

Characterizing epithelial‐mesenchymal transition‐linked heterogeneity in breast cancer circulating tumor cells at a single‐cell level

Molecular Oncology, EarlyView.
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa, Julia Richert, Tomasz Stokowy, Alicja Staśczak, Mariusz Szajewski, Maciej Ciesielski, Petra M. Grešner, Bartłomiej Tomasik, Łukasz Arcimowicz, Agnieszka Stankiewicz, Grażyna Suchodolska, Elżbieta Senkus, Wiesław Kruszewski, Anna J. Żaczek, Aleksandra Markiewicz   +14 more
wiley   +1 more source

Two decades of advances in clinical oncology - lessons learned and future directions. [PDF]

Nat Rev Clin Oncol
Banerjee S, Booth CM, Bruera E, Büchler MW, Drilon A, Fry TJ, Ghobrial IM, Gianni L, Jain RK, Kroemer G, Llovet JM, Long GV, Pantel K, Pritchard-Jones K, Scher HI, Tabernero J, Weichselbaum RR, Weller M, Wu YL.   +18 more
europepmc   +1 more source

UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology. [PDF]

Oncotarget, 2023
Price MJ, Nguyen AD, Byemerwa JK, Flowers J, Baëta CD, Goodwin CR.   +5 more
europepmc   +1 more source

The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity

Molecular Oncology, EarlyView.
Natural killer (NK) cells play a central role in anti‐melanoma immunity. However, melanoma cells adapt during co‐culture by upregulating CIITA and MHC II in response to interferon gamma (IFNγ), thereby evading NK‐cell lysis. Blocking IFNγ signaling or treatment with dimethyl fumarate/simvastatin counteracts this immune escape and maintains NK‐cell ...
Lena C. M. Krause, Rixa‐Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski   +6 more
wiley   +1 more source

Translating advocacy into action: exploring oncology healthcare professionals' awareness and use of the Clinical Oncology Society of Australia position statement on exercise in cancer care. [PDF]

Support Care Cancer
Dalla Via J, Cehic F, Peddle-McIntyre CJ, Andrew CR, Mizrahi D, Zissiadis Y, Spry NA, Newton RU, Kennedy MA.   +8 more
europepmc   +1 more source